HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Homeopathic Industry Loses Longtime Leader And Advocate, Jack Borneman

This article was originally published in The Rose Sheet

Executive Summary

American Association of Homeopathic Pharmacists says Borneman "contributed to monumental changes in the development of homeopathic drugs and their regulation" and "represented and defended homeopathy against uninformed regulation and vanity medical products masquerading as homeopathic."

You may also be interested in...



Homeopathic Firm Rebrands As Hyland’s Naturals With Shift To Focus On Supplement Market

Hyland’s Naturals focused for nearly 120 years on providing consumer health products in the pediatric and general wellness categories and is expanding into the women’s health and pet categories. Also will launch more than 20 natural wellness products over the next year.

OTC Homeopathy Group Revises Label Disclaimers In Light Of FTC Scrutiny

American Association of Homeopathic Pharmacists says its new recommended disclaimer for product labels – saying claims are not based on accepted medical evidence – is supported by research showing the language is clear to consumers. 

US FDA Moves Homeopathic Drug Enforcement To Risk-Based Approach

Products with routes of administration other than oral and topical or intended to be used for the prevention or treatment of serious or life-threatening diseases and conditions will be among those prioritized for enforcement and "regulatory actions," draft guidance notes.

Related Content

Topics

UsernamePublicRestriction

Register

RS121720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel